CNS Demyelinating Disease Evaluation, Serum




Test Mnemonic

CDS1SE

CPT Codes

  • 86053 - QTY (1)
  • 86363 - QTY (1)

Aliases

  • ADEM
  • AQP4
  • Aquaporin
  • MOG
  • NMO
  • Optic Neuritis Antibody
  • Transverse Myelitis Antibody
  • Vision Loss Antibody

Performing Laboratory

Mayo Clinic Dpt of Lab Med & Pathology


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
3 mLSerumNo additive (Red) RefrigeratedDraw 2 tubes to ensure adequate serum volume.

Alternate Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
3 mLSerumSST (Gold) RefrigeratedDraw 2 tubes to ensure adequate serum volume.

Minimum Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
2 mL     

Stability

Environmental Condition Description
Refrigerated28 days
Frozen28 days
Ambient72 hours

Days Performed

Mon, Tue, Thu

Turnaround Time

8 - 11 days

Methodology

Name Description
Fluorescent Activated Cell Sorting Assay (FACS) 

Special Info

Draw 2 tubes to ensure adequate serum volume. When the results of this assay require further evaluation of myelin oligodendrocyte glycoprotein (MOG-IgG1), the MOG-IgG1 titer will be performed at an additional cost. When the results of this assay require further evaluation of neuromyelitis optica (NMO)/Aquaporin-4-IgG, the neuromyelitis optica (NMO)/aquaporin-4-IgG titer will be performed at an additional charge. New York State approved. Grossly hemolyzed, lipemic or icteric specimens will be rejected.

Clinical Info

Diagnosis of inflammatory demyelinating diseases (IDDs) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis. Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy. Diagnosis of neuromyelitis optica (NMO). Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease. Diagnosis of ADEM. Prediction of a relapsing disease course. Aquaporin-4 (AQP4)-IgG and myelin oligodendrocyte glycoprotein (MOG)-IgG antibodies may drop below detectable levels in setting of therapies for acute attack (IV methylprednisolone or plasmapheresis) or attack prevention (immunosuppressants).